Snippets | GenomeWeb

Snippets

Premium

Epigenomics' 2008 Revenues Flat Year over Year; Net Loss Declines

German molecular diagnostics firm Epigenomics this week reported fiscal-year 2008 revenues of €2.6 million (US$3.4 million), flat with revenues of €2.6 million for 2007.

The company's FY 2008 net loss dropped 7 percent to €12.3 million, or €.47 per share, from €13.2 million, or €.74 per share.

The firm noted that its R&D costs declined 5 percent to €10 million from €10.5 million year over year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.